Administration of mannitol to prevent severe ovarian hyperstimulation syndrome: A randomized controlled trial

Middle East Fertility Society Journal

Volumn 8, Issue 2, 2003, Pages 159-163

  Saremi, Aboutaleb ^a,b   Alam, Mohammad ^a   Motaghi, Mina ^a  

^a Sarem Medical Center   (Iran)

^b NONE   (Iran)

Author keywords

ART; Mannitol; OHSS; Prevention

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; MANNITOL; PROGESTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0043165087     PISSN: 11105690     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N. Tucker M et al. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotropine releasing hormone. Lancet, 1985; 2: 13475-8.
2. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high-risk group. Hum Reprod, 1991; 6: 1345-1399.
3. Forman RG, Frydman R, Egan D: Severe ovarian hyperstimulation syndrome using agonists of gonadotrophin releasing hormone for in vitro fertilization: European series and a proposal for prevention. Fertil Steril, 1990; 53: 502-509.
4. Herman A, Ron-EL R, Golan A, Soffer Y, Bukovsky I, Caspi E, et al. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotrophin in in-vitro fertilization stimulated with gonadotropin-releasing hormone analogue and menotropins. Fert Ster, 1990; 53: 92-96.
5. Rizk B, Aboulghar M: Modern management of ovarian hyperstimulation syndrome. Hum Reprod, 1991, 6, 1082-1087.
6. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril, 1987; 48: 57-61.
7. Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhonr M et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biologic features. Hum Reprod, 1993; 8: 36-39.
8. Lightman A, Tarlatzis BC, Rzaso PJ, Culler MD, Caride VJ, Negro-Vilar AF et al. The ovarian Renin-Angiotensin system: Renin-like activity and Angiotensin immunoreactivity in gonadotropin-stimulated and unstimulated human follicular fluid. Am J Obstet Gynecol, 1987; 156: 808-816.
9. Mc Clure N, Leya J, Radwanska E, Row Lins R, Haning RV Jr: Luteal phase support and ovarian hyperstimulation. Hum Reprod, 1992; 7: 758-764.
10. Isipyk AZ, Kahraman S, Vicdan K, Aldybeyoglul, Ozgun OD,Polat G et al. Intravenous albumin combined with low dose human chorionic gonadotropin and late step-down administration of menotropins are effective in prevention of severe ovarian hyperstimulation in high risk patients in an in-vitro fertyilization program, Middle East Fertility Society Journal, 1997; 2(3): 238-42.
11. Isik A, Gokman O, Zeyneloglu HB, Kara S, Keles G, Guleldi B et al. Intravenous albumin prevents moderate-severe hyperstimulation in in-vitro fertilization patients: a randomized and controlled study. Eur J Obstet Gynecol Reprod Biol, 1996; 70: 179-83.
12. El-Sheikh MM, Hussein M, Fouad S, EL-Skeikh R, Bauer O, Al-Hasani S et al. Limited ovarian stimulation prevents recurrence of severe ovarian hyperstimulation syndrome in polycystic ovarian disease. Eur J obstet Gynecol Reprod Biol, 2001; 94(2): 245-9.
13. Golan A, Ronel R, Herman A, Soffer Y, weinraub Z, Caspi E et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv, 1989, 44, 430-440.
14. Dale PO, Tanbo T, Hauge E, Abyholm T. Low dose follicle stimulating hormone administration is a safe stimulation regimen even in previous hyper-responsive patients. Hum Reprod, 1992; 7: 1085-1089.
15. Son MY, Yoon SH, Lee SW, Son wy, Ko y, Yoon HG, Lim JH et al. Blastocyst development and pregnancies after IVF of mature oocytes retrieved from unstimulated patients with PCOS after in-vitro hCG priming. Hum Reproduction, 2002; 17(1): 134-6.
16. th ed., international edition, 1996: 695-7.
17. Ambuhl PM, Ballmer PE, Kraubenbuhl S, Krapf R et al. Quantification and predictors of plasma volume expansion from mannitol treatment. Intensive Care Med, 1997; 23: 1159-1164.
18. Seely JF, Dirks JH. Micropuncture study of hypertonic mannitol diuresis in the proximal and distal tube of the dog kidney. J Clinical Investigation, 1969; 48: 2330-2340.
19. Mac Dougall MJ, Tan SL, Balen AH, Jacobs HS et al. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod, 1993; 8: 223-237.
20. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone, Lancet, 1985; 2: 1357-78.
21. nd edition, 2000; 201.
22. Pride SM, James LST, Yuen BH. The ovarian hyperstimulation syndrome. Semin Reprod Endocrinol, 1990; 8: 247-60.
23. Ong A, Eisen V, Renine DP, Hornbarg R, Lachelin GC, Jacobs HS et al. The pathogenesis of ovarian hyperstimulation syndrome, Clin Endocrinol, 1991; 34: 43-48.
24. Bergh PA, Navot D. Ovarian hyperstimulation syndrome, a review of pathophysiology. J Assist Reprod Genet, 1992; 9: 429-438.
25. Paulson RJ, Do YS, Hsueh WA, Eggena P, Labo RA. Ovarian Rennin production invitro and in vivo characterization and Clinical correlation. Fertil Steril. 1989; 57: 634-638
26. Sealy JE, Gloriso N, Itkovitz J, Laragh JH. Prorenin as a reproductive hormone. New form of the Rennin system. Am J Med, 1986; 81: 1041-6.
27. Gloriso N, Atlas SA, Laragh JH, Jewelewicz R, Sealey JE: .Prorenin in high concentrations in human ovarian follicular fluid. Science, 1986; 233: 1422-4.